Tehran University of Medical Sciences Iranian Journal of Microbiology 2008-3289 4 3 2012 09 15 124 129 EN M Ghazi Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. G Khanbabaee Department of Pediatric Respiratory Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. F Fallah Pediatric Infectious Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. B Kazemi Cellular and Molecular Biology Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran. S Mahmoudi Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran. M Navidnia Pediatric Infectious Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. B Pourakbari Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran. B Bakhshi Department of Bacteriology, Tarbiat Modares University, Tehran, Iran. H Goudarzi Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2015 10 16 Background and Objectives: This study was carried out with the objective of determining the genomic variability of P. aeruginosa strains isolated from patients suffering from cystic fibrosis or from environmental cultures collected from different locations in the unit they admitted. Materials and Methods: A total of 57 clinical and environmental P. aeruginosa isolates were genotyped by enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR), and antimicrobial susceptibility testing was performed using the Clinical and Laboratory Standards Institute method. Results: One predominant ERIC profile (type A) was identified in 46 strains (81% of all typed isolates) which was responsible for thirty-nine of 44 clinical isolates (89%) and 7 of 13 environmental isolates (54%). All clinical isolates were susceptible to piperacillin-tazobactam, ceftazidime and cefepime followed by ticarcillin, aztreonam, amikacin and tobramycin (96.5%). Conclusions: In our country CF patients are not segregated from other patients, and transmission of bacteria between these patients and other patients might occur in the wards via personal contact or contaminated environment. Future evaluation for policy of patient segregation is necessary and the elimination of contaminated sources and control of  environmental spread and recurrent contamination risk is needed. https://ijm.tums.ac.ir/index.php/ijm/article/view/699 https://ijm.tums.ac.ir/index.php/ijm/article/download/699/468